Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer
Fuchs E, Schmidt L
Record ID 32018000626
English
Authors' objectives:
Bladder cancer (urothelial carcinoma) is the sixth most common cancer worldwide. The treatment of the heterogeneous group of non-muscle invasive bladder tumours (NMIBC) with a combination of intravesical chemotherapy with regional hyperthermia (HT) -i.e. radiofrequency induced intravesical chemohyperthermia (RF-CHT)- was the subject of the systematic review of the LBI-HTA. It was investigated whether RF-CHT is safer and more effective than other interventions.
Authors' recommendations:
The technology is considered experimental and should only be used in clinical trials.
Authors' methods:
To evaluate the effectiveness of RF-CHT, four RCTs and one NRCT were included (503 patients, 243 of them with RF-CHT).
Details
Project Status:
Completed
Year Published:
2020
URL for published report:
http://eprints.aihta.at/1257/1/DSD_122.pdf
URL for additional information:
http://eprints.aihta.at/1257/
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Austria
MeSH Terms
- Urinary Bladder Neoplasms
- Radiofrequency Therapy
- Hyperthermia, Induced
- Urothelium
Keywords
- Bladder cancer
- urothelial carcinoma
- oncology
- radiofrequency therapy
- hyperthermia
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.